By Dr Evan Brian Cunningham

Journal articles

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013

Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1

Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorienė L; Jarcuska P; Kåberg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Matičič M; Norris S; Ólafsson S; Øvrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', The Lancet Gastroenterology and Hepatology, 3, pp. 125 - 133, http://dx.doi.org/10.1016/S2468-1253(17)30284-4

Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S; Peacock A, 2017, 'Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review', The Lancet Global Health, 5, pp. e1192 - e1207, http://dx.doi.org/10.1016/S2214-109X(17)30375-3

Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L; Peacock A, 2017, 'Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review', The Lancet Global Health, 5, pp. e1208 - e1220, http://dx.doi.org/10.1016/S2214-109X(17)30373-X

Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040

Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020

Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002

Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701

Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007

Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420, http://dx.doi.org/10.1186/s12879-017-2517-3

Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10 Injecting risk behaviours among people who inject drugs in an Australian prison setting, 2005–2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16, http://dx.doi.org/10.1016/s2055-6640(20)30751-2

Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4 Acceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14, http://dx.doi.org/10.1016/s2055-6640(20)30745-7

Cunningham EB; Jacka B; DeBeck K; Applegate TL; Harrigan PR; Krajden M; Marshall BDL; Montaner J; Lima VD; Olmstead AD; Milloy MJ; Wood E; Grebely J, 2015, 'Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada', Drug and Alcohol Dependence, 152, pp. 272 - 276, http://dx.doi.org/10.1016/j.drugalcdep.2015.04.005

Cunningham EB; Applegate TL; Lloyd AR; Dore GJ; Grebely J, 2015, 'Mixed HCV infection and reinfection in people who inject drugs-impact on therapy', Nature Reviews Gastroenterology and Hepatology, 12, pp. 218 - 230, http://dx.doi.org/10.1038/nrgastro.2015.36

MacParland SA; Bilodeau M; Grebely J; Bruneau J; Cooper C; Klein M; Sagan SM; Choucha N; Balfour L; Bialystok F; Krajden M; Raven J; Roberts E; Russell R; Houghton M; Tyrrell DL; Feld JJ; Butt G; Conway B; Edwards A; Fischer B; Götte M; Kneteman N; Krahn M; Levy G; Liu Q; McGilvray I; Michalak T; Mugford G; Myers R; Ostrowski M; Pause A; Pezacki J; Richardson C; Schang L; Shoukry N; Sonenberg N; Soudeyns H; Tellier R; Tyndall M; Wilson J; Boisvert M; Depla M; Dupont B; Ehteshami M; Issur M; Olmstead A; Sarhan M; Siu R; Van Buuren N; Ablenas C; Bernier A; Cunningham E; Fabre T; Fahmy A; Hoffman B; Hyrina A; Kofahi H; Kulkarni A; Moqueet N; Ardakan NN; Singaravelu R; Thibault P; Wu Q; Artenie A; Puzhko S; Saeed S; Taylor N; Wong J; Cumming A, 2014, 'The 3rd Canadian symposium on Hepatitis c Virus: Expanding care in the interferon-free era', Canadian Journal of Gastroenterology and Hepatology, 28, pp. 481 - 487, http://dx.doi.org/10.1155/2014/704919

Conference Papers

Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3

Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S614 - S614, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7

Conference Posters

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham E; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', presented at International Liver Congress (European Association for the Study of the Liver (EASL 2018)), 11 April 2018 - 15 April 2018

Cunningham EB; Hajarizadeh B; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Bretana NA; Dolan K; Lloyd AR; Grebely J, 2018, 'A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING', Vol. 1, pp. 278 - 280, http://dx.doi.org/10.1093/jcag/gwy008.162

Conference Presentations

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', presented at Australasian Viral Hepatitis Conference, 13 August 2018 - 15 August 2018

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', presented at Australasian Viral Hepatitis Conference (AVHC), 10 August 2017 - 11 August 2017

Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6

Conference Abstracts

Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9

Howe A; De Salazar A; Aragri M; Popping S; Fourati S; Tay E; Rodrigo C; Cunningham E; Kjellin M; Fernando Fay F; Newton E; Sfalcin J; Gomes P; Boucher CA; De Knegt R; Poljak M; Lunar M; Salmon D; Usubillaga R; Sayan M; Mor O; Seguin-Devaux C; Lloyd A; Pawlotsky J-M; Grebely J; Lennerstrand J; Knops E; Kaiser R; Chulanov V; Rincon P; Martinez-Sapina A; Galera C; Douglas M; Silberstein FC; Harrigan R; Garcia Garcia F, 2019, 'GENOTYPE MISCLASSIFICATION NEGATIVELY IMPACT THE CHOICE OF REGIMENS AND TREATMENT OUTCOMES IN THE MANAGEMENT OF HEPATITIS C', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 318A - 319A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653501070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fourati S; Silberstein FC; Howe A; De Salazar A; Popping S; Di Maio VC; Tay E; Rodrigo C; Cunningham E; Kjellin M; Sfalcin J; Gomes P; Poljak M; Lunar M; Sayan M; Mor O; Salmon D; Usubillaga R; Seguin-Devaux C; Boucher CA; Poiteau L; Lloyd A; Grebely J; Lennerstrand J; Kaiser R; Zhigalkina P; Fernando Fay F; Aragri M; Chulanov V; Garcia-Deltoro M; Cabezas J; Carlos Alados J; De Knegt RJ; Douglas M; Garcia FG; Harrigan R; Pawlotsky J-M, 2019, 'HCV RESISTANCE PATTERNS IN A WORLDWIDE NETWORK OF COHORTS OF GT-3a INFECTED PATIENTS', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 180A - 181A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653500277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Popping S; Fourati S; Howe A; Di Maio VC; Tay E; Rodrigo C; Cunningham E; Kjellin M; Sfalcin J; Gomes P; Poljak M; Lunar M; Sayan M; Mor O; Salmon D; Usubillaga R; Omar M; Garcia-Bujalance S; Tellez F; Fuentes A; Seguin-Devaux C; Soulier A; Lloyd A; Grebely J; Aragri M; Lennerstrand J; Kaiser R; Zhigalkina P; Chulanov V; De Knegt RJ; Douglas M; Silberstein FC; Harrigan R; Garcia FG; Boucher CA; Pawlotsky J-M, 2019, 'THE GLOBAL PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS (RASS) IN "UNUSUAL" HCV SUBTYPES', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 77A - 78A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653500117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kearley J; Gilliver R; Lothian R; Cunningham EB; Dore GJ; Read P, 2019, 'MAXIMISING ADHERENCE TO DIRECT-ACTING ANTI-VIRALS FOR HEPATITIS C AMONG STREET-BASED AND MARGINALISED CLIENTS USING AN OPIOID AGONIST TREATMENT PROGRAM: THE RESULTS OF DAILY DOSING', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30450-6

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Reports

Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney

Preprints

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, , http://dx.doi.org/10.2139/ssrn.3213670

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, , http://dx.doi.org/10.2139/ssrn.4267510

Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis, , http://dx.doi.org/10.2139/ssrn.4267527

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, , http://dx.doi.org/10.2139/ssrn.3709824

Back to profile page